Navigation Links
Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
Date:8/25/2008

COMPANY PRESENTS AT THOMAS WEISEL WEDNESDAY, SEPTEMBER 3RD AND NEWSMAKERS

IN THE BIOTECH INDUSTRY CONFERENCE THURSDAY, SEPTEMBER 4TH

SAN DIEGO, Aug. 25 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer will be presenting at both the Thomas Weisel Healthcare Conference in Boston and the NewsMakers in the Biotech Industry Conference in New York.

The presentation at the Thomas Weisel Conference in Boston at the Four Seasons takes place Wednesday, September 3, 2008 at 2:05 p.m. Eastern Time (ET) / 11:05 a.m. Pacific Time (PT). The live presentation will be simultaneously webcast and may be accessed on the Company's website at http://www.neurocrine.com.

The presentation at the NewsMakers in the Biotech Industry Conference in New York at the Millennium Broadway will take place Thursday, September 4, 2008 at 10:00 a.m. Eastern Time (ET) / 7:00 a.m. Pacific Time (PT). The live presentation will be simultaneously webcast and may be accessed on the Company's website at http://www.neurocrine.com.

If you are unable to attend these webcasts and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600. Viewers are encouraged to visit the website approximately 5 minutes prior to the presentations to download or install any necessary software. A replay of both presentations will be available approximately one hour after the conclusion of the live event and will be archived on the Company's website for two weeks.

About Neurocrine

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome (IBS), anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurocrine Biosciences Reports Second Quarter 2008 Results
2. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
3. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
6. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
7. Neurocrine Announces Work Force Restructuring
8. Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA
9. Neurocrine Biosciences Announces Conference Call and Webcast to Provide Indiplon Update
10. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):